| |
||
|
Catalogue Number |
Product | Order number / Unit |
| |
||
| 9921 | PSMA-11 (GMP) |
Please inquire for customized filling and bulk quantities.
|
|
Precursor for [68Ga]GaPSMA-11
PSMA: prostate-specific membrane antigen |
||
| Manufactured according to GMP requirements for APIs for use in clinical trials (ICH Q7 chapter 19) | ||
| Molar Mass: 947.0 (net peptide) | ||
| C44H62N6O17 ⋅ x CF3CO2H | ||
| [1366302-52-4] | ||
| Colourless to off-white solid packaged in plastic vials | ||
| Purity: ≥ 96 % | ||
|
Certificates:
CoA with ESI-MS and NMR (identity); HPLC (purity) ; GC (residual solvents); heavy metals content (ICP-MS); microbiology test |
||
|
Chemical Name: CA index name: 4,6,12,19-Tetraazadocosane-1,3,7-tricarboxylic acid, 22-[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl]-5,13,20-trioxo-, (3S,7S)-, supplied as trifluoroacetate salt |
||
|
Synonymes: PSMAHBED; Glu-CO-Lys(Ahx)-HBED-CC; Glu-NH-CO-NH-Lys(Ahx)-HBED-CC; 2-[3-(1-Carboxy-5-{6-[3-(3-{[(2-{[5-(2-carboxy-ethyl)-2-hydroxy-benzyl]-carboxymethyl-amino}-ethyl)-carboxymethyl-amino]-methyl}-4-hydroxy-phenyl)-propionylamino]-hexanoylamino}- |
||
|
Literature: Eder M. et al. Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals. 2014, 7, 779-796. |
||
| Eder M. et al. 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chem. 2012, 23, 688-697. | ||
| date of product catalogue issue: 10 May 2017 | ||